Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sildenafil/Viagra in the treatment of premature ejaculation


The arrival of Pfizer’s blue pill Sildenafil in 1998 brought a great relief both to patient and physician signalling the start of a great era of medical therapy in sexual medicine. Since then the sexual medicine experts have been prescribing sildenafil in erectile dysfunction with acceptable minor adverse events. But the use of sildenafil in premature ejaculation (PE) is still debated. 2018 being the 20th anniversary of sildenafil, we have compiled interesting facts about the role of sildenafil in PE from various original articles, systematic reviews, meta-analyses, economic brochures and sexual medicine committee guidelines. The major issues in most of these studies were the heterogeneity in the definition of PE and estimating the exact ejaculatory latency time. This perspective article highlights the positive role of sildenafil in the management of PE (even without ED) with acceptable adverse events. Now that we have a standardised definition of PE from International Society of Sexual Medicine (ISSM) and a psychogenic component in PE definition, more randomised placebo-controlled studies are required to further establish its role.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 20895ltr.pdf [Internet]. Available from: [cited 2018 Oct 27]

  2. Keith A. The economics of Viagra. Health Aff Proj Hope. 2000;19:147–57.

    CAS  Article  Google Scholar 

  3. A History of Viagra. Available from:; 2017 Dec 11 [cited 2018 Oct 27]

  4. Pfizer to lose patent of drug Viagra, Indian companies gear up with copycat versions [Internet]. 2018. Available from: [cited 2018 Sep 21]

  5. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014;11:1423–41.

    Article  Google Scholar 

  6. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, Waldinger MD, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2010;7(4 Pt 2):1668–86.

    Article  Google Scholar 

  7. Hull EM, Du J, Lorrain DS, Matuszewich L. Extracellular dopamine in the medial preoptic area: implications for sexual motivation and hormonal control of copulation. J Neurosci. 1995;15:7465–71.

    CAS  Article  Google Scholar 

  8. Donatucci CF. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med. 2006;3(Suppl. 4):S303–S8.

    Article  Google Scholar 

  9. Sato Y, Zhao W, Christ GJ. Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. Am J Physiol Regul Integr Comp Physiol. 2001;281:R269–278.

    CAS  Article  Google Scholar 

  10. Dixon JS, Jen PY. Development of nerves containing nitric oxide synthase in the human male urogenital organs. Br J Urol. 1995;76:719–25.

    CAS  Article  Google Scholar 

  11. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol. 2007;52:1331–9.

    Article  Google Scholar 

  12. Abdel-Hamid IA, Jannini EA, Andersson K-E. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009;13:175–93.

    CAS  Article  Google Scholar 

  13. Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA. Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J Sex Med. 2009;6:408–14.

    Article  Google Scholar 

  14. Birowo P, Uckert S, Kedia GT, Sonnenberg JE, Sandner P, Thon WF, et al. Exposure of human seminal vesicle tissue to phosphodiesterase (PDE) inhibitors antagonizes the contraction induced by norepinephrine and increases production of cyclic nucleotides. Urology 2010;76:1518.e1-6.

  15. Orhan I, Onur R, Taşdemir C, Ayar A, Kadioğlu A. Sildenafil citrate inhibits agonist induced contractions in isolated rat seminal vesicles. J Urol. 2006;175:2350–3.

    CAS  Article  Google Scholar 

  16. McMahon CG, Stuckey BGA, Andersen M, Purvis K, Koppiker N, Haughie S, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2:368–75.

    CAS  Article  Google Scholar 

  17. ISSM-Quick-Reference-Guide-to-PE.pdf [Internet]. Available from: [cited 2018 Sep 21]

  18. Hatzimouratidis K, Eardley I, Giuliano F, Moncada I, Salonia A. Male sexual dysfunction [Internet]. Uroweb. Available from: [cited 2018 Sep 21].

  19. McMahon CG. Current and emerging treatments for premature ejaculation. Sex Med Rev. 2015;3:183–202.

    Article  Google Scholar 

  20. Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016;10:1401–7.

    Article  Google Scholar 

  21. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JPW, Lue TF, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004;172:290–4.

    Article  Google Scholar 

  22. Jannini EA, McMahon C, Chen J, Aversa A, Perelman M. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med. 2011;8:2135–43.

    Article  Google Scholar 

  23. Wang W-F, Wang Y, Minhas S, Ralph DJ. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol J Jpn Urol Assoc. 2007;14:331–5.

    CAS  Google Scholar 

  24. Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy AE-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab J Urol. 2013;11:392–7.

    Article  Google Scholar 

  25. Gökçe A, Halis F, Demirtas A, Ekmekcioglu O. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int. 2011;107:1274–7.

    Article  Google Scholar 

  26. Shaeer O. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10:532–40.

    CAS  Article  Google Scholar 

  27. Men C, Yu L, Yuan H, Cui Y. Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis. Andrologia. 2016;48:978–85.

    CAS  Article  Google Scholar 

  28. Bai Y, Pu C, Han P, Li J, Yuan H, Tang Y, et al. Selective serotonin reuptake inhibitors plus phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Urology. 2015;86:758–64.

    Article  Google Scholar 

  29. Sun Y, Luo D, Yang L, Tang C, Yang T, Hu X, et al. Efficacy of phosphodiesterase-5 inhibitor in men with premature ejaculation: a new systematic review and meta-analysis. Urology. 2015;86:947–54.

    Article  Google Scholar 

  30. Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: a randomised placebo-controlled clinical trial. Andrologia. 2018;50.

  31. Martyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, et al. Phosphodiesterase Type 5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Eur Urol Focus. 2017;3:119–29.

    Article  Google Scholar 

  32. Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Bella AJ, et al. Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology. 2009;74:831–836.e8.

    Article  Google Scholar 

  33. McMurray JG, Feldman RA, Auerbach SM, DeRiesthal H, Wilson N. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007;3:975–81.

    CAS  Google Scholar 

  34. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164–71.

    CAS  Article  Google Scholar 

  35. Moschos MM, Nitoda E. Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drug Des Devel Ther. 2016;8:3407–13.

    Article  Google Scholar 

  36. Wirostko BM, Tressler C, Hwang L-J, Burgess G, Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. Br Med J. 2012;344:e554.

    Article  Google Scholar 

  37. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med. 2006;3:12–27.

    CAS  Article  Google Scholar 

  38. Pentyala S, Rahman A, Mishra S, Muthiki S, Hughes E, Bikkani A, et al. Pharmacokinetic drug interactions of phosphodiesterase-5 inhibitors mediated by cytochrome P450 3A4 isoform. 10.

  39. Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): ejaculatory function, penile anatomy, and contraceptive usage among Arabic-speaking Internet users in the Middle East. J Sex Med. 2012;9:425–33.

    Article  Google Scholar 

  40. Shaeer O, Shaeer K, Serefoglu EC, Fode M. 381 Premature ejaculation among english-speaking male internet users in the USA: Results From the Global Online Sexuality Survey (GOSS) 2015. J Sex Med. 2017 (1):S112–3.

  41. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int. 2006;98:259–72.

    CAS  Article  Google Scholar 

  42. Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, et al. Standards for Clinical Trials in Male and Female Sexual Dysfunction: III. Unique Aspects of Clinical Trials in Male Sexual Dysfunction. J Sex Med. 2017;14:3–18.

    Article  Google Scholar 

  43. Tang W, Ma L, Zhao L, Liu Y. Efficacy and safety of Sertraline, Viagra and Cardura in patients with premature ejaculation [Internet]; 2014. Available from: [cited 2018 Sep 21]

  44. Kim SW, Paick JS. Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology. 1999;54:544–7.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Pramod Krishnappa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Krishnappa, P., Fernandez-Pascual, E., Carballido, J. et al. Sildenafil/Viagra in the treatment of premature ejaculation. Int J Impot Res 31, 65–70 (2019).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links